Octreotide nasal spray for diabetic macular edema
Treatments studied
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This study tests whether an octreotide nasal spray can reduce swelling in the center of the retina caused by diabetic macular edema. It's an early-phase trial for people with diabetes who have not had recent eye treatments or certain medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 90 years old.
- You have diabetic macular edema (swelling in the center of your retina) with vision between 20/32 and 20/200.
- You have not had eye laser treatment in the last 6 months or eye injections for this condition in the last 3 months.
- You are not currently taking anti-inflammatory medications (like steroids, immune drugs, or certain pain relievers).
- You are not allergic to octreotide and have not used it in the last 2 months.
- Your liver and kidney function tests are within normal limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called CU06-1004 for people with diabetic macular edema (swelling in the center of the retina caused by diabetes). It aims to see if the drug can improve vision and reduce swelling.
This Phase 1 study tests the safety and early effectiveness of OCU200 eye injections in people with diabetic macular edema (DME) that affects the center of vision. It may help by reducing the eye swelling that blurs vision from diabetes.
This Phase 3 study compares a new eye injection (RC28-E) with the standard treatment (aflibercept) for diabetic macular edema, which is swelling in the central retina that affects vision. It aims to see whether the new treatment works as well and is safe.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
This study tests whether a medication called dapagliflozin, which is usually used for diabetes and heart failure, can help reduce swelling in the retina (diabetic macular edema) and improve vision. It is for people with type 2 diabetes who are already taking insulin and metformin.
This Phase 1 trial tests MS-553 to see how it works and how safely it can be given to people with diabetic retinopathy causing central macular swelling (macular edema). You may be considered if your vision and eye scan results match, and if you can follow frequent study visits.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.